Ryan Sullivan, MD

Ryan Sullivan, MD, discusses RP1 plus nivolumab in patients with advanced melanoma who progressed on prior anti–PD-1 therapy.

Omid Hamid, MD, and Ryan Sullivan, MD, discuss what they look forward to in the future of metastatic uveal melanoma treatment.

Experts highlight strategies for managing the adverse events of tebentafusp, especially cytokine release syndrome.

Dr Ryan Sullivan details clinical trial data presented at ASCO 2022 on the use of tebentafusp for mUM.

Dr Omid Hamid explains the mechanism of action of recently approved tebentafusp for mUM, and why HLA testing is necessary for patients being considered for the treatment.

Ryan Sullivan, MD, provides an overview of metastatic uveal melanoma, currently available treatment options, and unmet needs in the field.

Ryan J. Sullivan, MD, discusses the examination of tebentafusp-tebn in uveal melanoma.

Ryan Sullivan, MD, discusses the future of triplet therapies for patients with melanoma.

Ryan Sullivan, MD, discusses treatment sequencing with targeted therapy and immunotherapy in melanoma.

Ryan Sullivan, MD, discusses treatment options in BRAF-mutant melanoma.

Ryan Sullivan, MD, Massachusetts General Hospital, discusses how best to treat patients with melanoma who have the BRAF mutation.